Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 16/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | XBP1 | P17861 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19831036 | 0.85 | ALOX15 (0.74) | ALOX15ALDH1A1CYP1A2HPGDXBP1 | |
| SCHEMBL4358217 | 0.85 | ALOX15 (0.81) | ALOX15ALDH1A1CYP1A2HPGDXBP1 | |
| SCHEMBL8793660 | 0.84 | ALOX15 (0.85) | ALOX15ALDH1A1CYP1A2HPGDXBP1 | |
| SCHEMBL16235594 | 0.81 | ALOX15 (0.83) | ALOX15ALDH1A1CYP1A2HPGDXBP1 | |
| SCHEMBL19831031 | 0.80 | ALOX15 (0.77) | ALOX15ALDH1A1CYP1A2HPGDXBP1 | |
| SCHEMBL19831042 | 0.80 | ALOX15 (0.72) | ALOX15ALDH1A1CYP1A2HPGDXBP1 | |
| SCHEMBL11297387 | 0.79 | ALDH1A1 (0.82) | ALOX15ALDH1A1CYP1A2HPGDXBP1 | |
| SCHEMBL21465547 | 0.79 | TUBB4A (0.74) | ALOX15ALDH1A1CYP1A2HPGDXBP1 | |
| SCHEMBL3029308 | 0.78 | ALOX15 (0.74) | ALOX15ALDH1A1CYP1A2HPGDXBP1 | |
| SCHEMBL4042096 | 0.78 | ALOX15 (0.74) | ALOX15ALDH1A1CYP1A2HPGDXBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130211079-A1 | SUBSTITUTED HETEROCYCLES AS THERAPEUTIC AGENTS FOR TREATING CANCER | DOEMLING ALEXANDER (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130211079-A1 | SUBSTITUTED HETEROCYCLES AS THERAPEUTIC AGENTS FOR TREATING CANCER | DOEMLING ALEXANDER (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130211079-A1 | SUBSTITUTED HETEROCYCLES AS THERAPEUTIC AGENTS FOR TREATING CANCER | DOEMLING ALEXANDER (US) | 2013-08-15 | — | — | US | disclosed |
| US-20110313167-A1 | Substituted Heterocycles as Therapeutic agents for treating cancer | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2011-12-22 | — | — | US | disclosed |
| US-20110313167-A1 | Substituted Heterocycles as Therapeutic agents for treating cancer | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2011-12-22 | — | — | US | disclosed |
| US-20110313167-A1 | Substituted Heterocycles as Therapeutic agents for treating cancer | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110313167-A1 | Substituted Heterocycles as Therapeutic agents for treating cancer | TP53, MDM4, MDM2 | ALOX15 3298/4885ALDH1A1 2723/4885CYP1A2 3242/4885 |
| US-20130211079-A1 | SUBSTITUTED HETEROCYCLES AS THERAPEUTIC AGENTS FOR TREATING CANCER | TP53, MDM4, MDM2 | ALOX15 3298/4885ALDH1A1 2723/4885CYP1A2 3242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.